HER2 ANTIBODY-DRUG CONJUGATES

• Main Authors: LIN, Shih-Yao, LEE, Shu-Hua, HSIEH, Yu-Chi, HUANG, Chiu-Chen, TSAI, Yu-Ying, LIN, Rong-Hwa
• Format: Patent
• Language: English
• Published: 30.01.2019

HER2 ANTIBODY-DRUG CONJUGATES The present disclosure provides compounds with a hydrophilic self-immolative linker, which is cleavable under appropriate conditions and incorporates a hydrophilic group to provide better solubility of the compound. The compounds of the present disclosure comprise a drug moiety, a targeting moiety capable of targeting a selected cell population, and a linker which contains an acyl unit, an optional spacer unit for providing distance between the drug moiety and the targeting moiety, a peptide linker which can be cleaved under appropriate conditions, a hydrophilic self-immolative linker, and an optional second self-immolative spacer or cyclization self-elimination linker. In some aspects of the present disclosure, the targeting moiety is an anti-HER2 antibody. The present disclosures further provide compositions and methods for treating cancers. Figure 4